Text Size

Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV

This study has been completed.
Sponsor:
Information provided by:
Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier:
NCT00329251
First received: May 22, 2006
Last updated: NA
Last verified: May 2006
History: No changes posted

May 22, 2006
May 22, 2006
April 2003
Not Provided
Times viral load increases over 20.000 copies/mL.
Same as current
No Changes Posted
  • Development of resistance to antiretroviral therapy during the 18 months of the study
  • Appearance of specific CD4 proliferative responses against HIV during the 18 months of the study
  • Appearance of specific cytotoxic responses against HIV during the 18 months of the study
  • Number of patients under 5000 copies/mL after 6 months of stopping HAART
  • Development of symptoms C during the 18 months of the study
  • Deaths during the 18 months of the study
  • Toxicity during the 18 months of the study
Same as current
Not Provided
Not Provided
 
Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV
Study of the Influence of Immunological Repeated Stimuli With Commercial Vaccines Over the Viral Load (VL), Resistance Development and Specific Immunological Response Against HIV in Early Stage HIV Patients With Undetectable VL After HAART

The purpose of this study is to determine whether an immunization schedule is beneficial to HIV-infected patients with CD4 recount over 500 cells/mm3 and undetectable viral load.

As HIV-infected patients are considered immunocompromised, it is generally recommended that they have to receipt appropriate vaccines. However data are conflicting concerning potential harmful effects following the administration of commercial vaccines in HIV-infected patients. Transient increases (“blips”) in the viral load have been described associated with a single dose of vaccine, with the potential risk of developing resistance to HAART. On the other hand, there has been described that patients with blips can have an increase in HIV-specific immune responses, which may help to improve the viral control.

Comparison: We have performed a clinical trial to evaluate the effect of a vaccination program in successfully treated HIV-infected adults on HAART compared to placebo.
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
HIV
  • Biological: Hepatitis A
  • Biological: Hepatitis B
  • Biological: Influenza
  • Biological: Pneumococcal
  • Biological: Tetanus-diphteria
  • Biological: Varicella
  • Biological: Measles-Mumps-Rubella
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
26
March 2006
Not Provided

Inclusion Criteria:

  • Age >18 years
  • Asymptomatic HIV infection
  • CD4>500/mm3 >6 months prior to inclusion
  • CD4 nadir >300/mm3
  • Being under HAART > 1 year prior to inclusion
  • Viral load<200 copies/mL > 6 months prior to inclusion
  • Viral load previous to treatment >5000 copies/mL
  • Informed consent

Exclusion Criteria:

  • Pregnant women
  • Basal creatinine >2.5 mg/dL
  • Allergy to either a vaccine or a ingredient of it
  • Chronic hepatitis B
  • GOT/GPT > 250 IU/L
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00329251
02-0490; EARTH-06, VAC-01
Not Provided
Not Provided
Hospital Clinic of Barcelona
Not Provided
Study Chair: José Mª Gatell, MD Hospital Clínic of Barcelona
Study Chair: José Mª Miró, MD Hospital Clínic of Barcelona
Study Chair: José Mª Bayas, MD Hospital Clínic of Barcelona
Hospital Clinic of Barcelona
May 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP